Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Trial Profile

A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-067
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Jun 2019 Results assessing long-term QoL from CM 067 during the TFI (period off study tx and free of subsequent therapy), based on an updated 4-y dataset presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results of pooled analysis from Checkmate 067 and 069 exploring the sensitivity of treatment-free survival, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2019 Results assessing patient-reported outcomes (PRO) for QoL over a 4-year period, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top